logo

For the Inventor, By the Inventor

Sunnyvale, CA, United States of America

Pharmacyclics, Inc.


USPTO Granted Patents = 194

% Expired Patents = 6.7



Trademarks = 7

Forward Citations = 6,306

Loading Chart...
Loading Chart...

113 inventors (with patents filed for the assignee):

goldMedal Erik J Verner (65 out of 83 patents)

silverMedal Lee Honigberg (52 out of 53 patents)

bronzeMedal Joseph J Buggy (46 out of 51 patents)

4.  David J Loury (43 out of 46 patents)

5.  Tarak D Mody (39 out of 54 patents)

6.  Zhengying Pan (39 out of 39 patents)

7.  Wei Yu Chen (28 out of 113 patents)

8.  Jonathan L Sessler (26 out of 89 patents)

9.  Darren Magda (24 out of 39 patents)

10.  Norbert Purro (19 out of 19 patents)

11.  Sriram Balasubramanian (14 out of 16 patents)

12.  Mark Stephen Smyth (14 out of 41 patents)

13.  Laurence Elias (13 out of 16 patents)

14.  Erick A Goldman (13 out of 25 patents)

15.  David Dale Wirth (13 out of 30 patents)


Core Competencies:
Bruton's Tyrosine Kinase
Kinase Inhibitors
Pharmaceutical Formulations
Crystalline Forms
Solid Tumors
Fibrosis Treatment
Histone Deacetylase
Adjuvant Therapy
Resistance Mutations

194 patents:

1. 12551448 - Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor (2026-02-17),
2. 11672803 - Use of inhibitors of Brutons tyrosine kinase (Btk) (2023-06-13),
3. 10961251 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2021-03-30),
4. 10954567 - Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) (2021-03-23),
5. 10898461 - Salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl) phenoxy]ethyli-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same (2021-01-26),
6. 10828259 - Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor (2020-11-10),
7. 10752634 - Crystalline forms of a brutons tyrosine kinase inhibitor (2020-08-25),
8. 10751342 - Use of inhibitors of Bruton's tyrosine kinase (Btk) (2020-08-25),
9. 10695350 - Methods of treating and preventing graft versus host disease (2020-06-30),
10. 10653696 - Use of inhibitors of bruton's tyrosine kinase (BTK) (2020-05-19),
11. 10478439 - Use of inhibitors of bruton's tyrosine kinase (Btk) (2019-11-19),
12. 10463668 - Methods of treating and preventing graft versus host disease (2019-11-05),
13. 10294232 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2019-05-21),
14. 10294231 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2019-05-21),
15. 10266540 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2019-04-23),
Pharmacyclics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of cancer. With a focus on targeted therapies, Pharmacyclics aims to improve patient outcomes and quality of life. Visit their website for more information.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Pharmacyclics, Inc.
194 Patents

#28 in Sunnyvale, CA

#462 in California

#2,120 in US

#4,333 in the World

Sunnyvale, CA (US)
Sunnyvale, CA, United States of America

Pharmacyclics, Inc.

Forward Citations = 6,306

113 inventors:

goldMedal Erik J Verner (65 out of 83 patents)

silverMedal Lee Honigberg (52 out of 53 patents)

bronzeMedal Joseph J Buggy (46 out of 51 patents)

4.  David J Loury (43 out of 46 patents)

5.  Tarak D Mody (39 out of 54 patents)

Please report any incorrect information to [email protected]
Loading…